Details of the Drug

General Information of Drug (ID: DM0LK0V)

Drug Name

NGM438

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte-associated Ig-like receptor 1 (LAIR1)	TTSI7A8	LAIR1_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05311618) A Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of NGM Biopharma